

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

[Refer a Patient](#)

[Refer a Patient](#)

## The Ping Chi Lab

### ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

-----



Ping Chi, MD, PhD


Member, Human Oncology and Pathogenesis Program

---

It is well recognized that the cellular context contributes to susceptibility to oncogenic transformation mediated by different “driver” oncogenes. The focus of our laboratory is to discover and understand the critical genetic and epigenetic factors that determine the cellular-context-dependent oncogenesis in distinct cancer types, with a primary focus on sarcoma and melanoma. We use multimodality approaches, including transcriptome analyses, epigenome mapping, and gene-expression-based high-throughput screens, as well as murine models to understand the mechanisms of pathogenesis and to develop

biomarkers and targeted therapies based on insight into disease pathogenesis.

[View Lab Overview](#) →



## Featured News


### EVENT



[2017 MSK Convocation and Commencement Ceremony Celebrates Distinguished Scientists and Young Scholars](#)

Degrees were presented and awards were given at the 38th annual ceremony held on May 18.

#### IN THE LAB



### [Molecular Studies Provide New Clues about Rare Soft Tissue Sarcoma](#)

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

#### ANNOUNCEMENT



### [Geoffrey Beene Rock Stars of Science™ Campaign Features Memorial Sloan Kettering Researchers](#)

The initiative, focused on investigators from Memorial Sloan Kettering's Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

[View All Featured News](#)

## Publications Highlights

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y\*, Chi P\*. [PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry](#). Cancer Discovery. 2022 Jul 5;cd.21.1671. doi: 10.1158/2159-8290.CD-21-1671. Online ahead of print. PMID: 35789380; Featured in "In the Spotlight".

Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG, Wong EWP, Miranda-Román MA, Yang N, Wang Y, Pachai MR, Sher J, Giff E, Tang F, Khurana E, Singer S, Liu Y, Galbo PM Jr, Maag JL, Koche RP, Zheng D, Antonescu C, Deng L, Li M, Chen Y\*, Chi P\*. *Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses*. Journal of Clinical Investigation. 2022 Jul 19:e153437. doi: 10.1172/JCI153437. Epub ahead of print. PMID: 35852856.

---

Chi P\*, Qin LX, Nguyen B, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. [Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor](#). Journal of Clinical Oncology. 2022;40(9):997-1008. PMCID: PMC8937014.

---

Chi P\*, Qin LX, Camacho N, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD\*. [Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors](#). Clinical Cancer Research. 2022;28(8):1507-1517. PMCID: PMC9012681.

---

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. [Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets](#). Science. 2022; 376(6596):eabe1505. PMCID: PMC9299269.

[View All Publications](#)

## People



## Ping Chi, MD, PhD

*Member, Human Oncology and Pathogenesis Program*

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.

MD, Weill Cornell Medical College

PhD, The Rockefeller University

[View physician profile](#)

Physician profile

## Members

Subha  
Baniya

GSK Graduate Student

Vaishnavi Reeya  
Callychurn

Research Technician

Woo Hyun (Alex)  
Cho

Research Technician






Sarah  
Qadir  
Laboratory Admin




Fanny  
Tomas  
Research Fellow




Elissa Wai Pung  
Wong  
Senior Research Scientist



Juan Yan  
Research Scholar



Yang Zeng  
Research Scholar



Tao  
Zhang  
Research Associate

Lab Alumni  
+

Lab Affiliations  
+

## Achievements

Kimmel Scholar Award, Sidney Kimmel Foundation (2012)

Research Grant, Sarcoma Foundation of America (2012)

Grant, GIST Cancer Awareness Foundation (2012)

Director's New Innovator Award, National Institutes of Health (2012)

Clinical Scientist Development Award, National Institutes of Health (2011)

## Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

---

## Career Opportunities

[Apply now](#) →

## Get in Touch

 [646-888-3349](tel:646-888-3349)

Lab Phone

## Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ping Chi discloses the following relationships and financial interests:

Boxer Capital, LLC

Professional Services and Activities

Deciphera

Professional Services and Activities



Ningbo NewBay Medical Technology Co., Ltd.

Professional Services and Activities (Uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures](#) →

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center